Nouscom Raises €120 Million for Cancer Immunotherapy Push

Swiss biotech Nouscom has raised €120 million to move its innovative cancer immunotherapy closer to clinical trials, EU-Startups reports.

The round ranks among the larger recent financing rounds for a European biotech working on immuno-oncology. Nouscom develops treatments that train the immune system to attack tumors. The €120 million gives the company the runway to advance its lead programs from preclinical work toward testing in patients.

What does the funding change for Nouscom?

The money buys time and clinical proof points. Clinical trials are the most expensive and most decisive stage in drug development. A company that cannot fund them stalls; a company that can, gets a chance to show whether its science works in humans.

Nouscom now has that chance. EU-Startups reports that the financing brings the company's innovative cancer immunotherapy closer to clinical trials. That single step — from laboratory and animal data to human dosing — is where most experimental therapies either prove their value or fail. Investors who commit €120 million at this stage are betting that Nouscom's platform has enough early evidence to justify the cost and risk of that transition.

Why does cancer immunotherapy attract this level of capital?

Immunotherapy has reshaped cancer treatment over the past decade. Instead of attacking tumors directly with chemotherapy or radiation, these drugs unlock the body's own immune defenses against cancer cells. The approach has produced some of oncology's biggest commercial successes, and it continues to attract outsized investment across the sector.

Nouscom works within that field. The company is based in Switzerland, a country with a dense cluster of pharmaceutical companies, research institutions and specialized investors. A €120 million raise fits the profile of a biotech preparing for the steep costs of clinical development, where a single trial can consume tens of millions of euros before a product ever reaches the market.

What is the structure of the story?

The mechanism here is straightforward. Nouscom holds an innovative immunotherapy candidate. That candidate needs clinical trials to demonstrate safety and effectiveness in humans. Clinical trials need capital. The €120 million supplies it.

For the investors, the bet works like this: if the therapy succeeds in trials, the company's value rises sharply, either through a acquisition by a large pharmaceutical company or through eventual commercialization. If it fails, the capital is lost. Biotech investing at this stage is a portfolio game, and large rounds reflect conviction in both the science and the team.

Who reported the deal?

EU-Startups, a publication covering the European startup ecosystem, reported the financing. The report identifies the company as Switzerland-based Nouscom, the amount as €120 million, and the purpose as advancing an innovative cancer immunotherapy toward clinical trials.

What comes next?

The next milestones for Nouscom are clinical ones: filing to begin trials, dosing the first patients, and releasing early safety data. Each step will determine whether the €120 million becomes the foundation of a marketed therapy or a lesson in the economics of drug development. For now, the company has the capital to find out.